-transparent.png){kind=logo}
Treatment of human immunodeficiency virus (HIV) infection continues to be a challenge. Drug regimens that include two nucleoside reverse transcriptase inhibitors and a protease inhibitor are now the standard of care. These regimens require strict patient adherence and have numerous adverse effects at a high cost, so clinicians must continue to explore other therapeutic options. Hydroxyurea is a ribonucleotide reductase inhibitor that may have efficacy against HIV. We conducted a critical review of the literature to examine the utility of hydroxyurea-based drug combinations.
Related Publications
F Romanelli, and
C Pomeroy, and
K M Smith
November 1994,
Science (New York, N.Y.),
F Romanelli, and
C Pomeroy, and
K M Smith
January 2011,
Bioorganic & medicinal chemistry letters,
F Romanelli, and
C Pomeroy, and
K M Smith
May 2003,
Antiviral research,
F Romanelli, and
C Pomeroy, and
K M Smith
October 2005,
AIDS research and human retroviruses,
F Romanelli, and
C Pomeroy, and
K M Smith
October 1987,
The Journal of experimental medicine,
F Romanelli, and
C Pomeroy, and
K M Smith
February 1990,
Antimicrobial agents and chemotherapy,
F Romanelli, and
C Pomeroy, and
K M Smith
September 2008,
Antimicrobial agents and chemotherapy,
F Romanelli, and
C Pomeroy, and
K M Smith
March 2010,
PloS one,
F Romanelli, and
C Pomeroy, and
K M Smith
January 1999,
Journal of biological regulators and homeostatic agents,
F Romanelli, and
C Pomeroy, and
K M Smith
August 2008,
Journal of medicinal chemistry,
